{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:28:04Z","timestamp":1786541284829,"version":"build-2736575974"},"reference-count":25,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Laryngoscope"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Given the unprecedented rise in glucagon\u2010like peptide\u20101 receptor analogue (GLP\u20101RA) therapy over the past decade, we aimed to investigate potential unintended laryngeal manifestations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study was conducted using the TriNetX United States Collaborative Network. Adults with obesity on GLP\u20101RA medications (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009617,296) from January 1, 2016 to December 3, 2025, were compared with controls (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093,503,102), excluding patients with head and neck neoplasms, head and neck radiation therapy, autoimmune diseases, airway disorders or acute respiratory conditions via ICD\u201010 and CPT codes. Laryngeal symptoms within 1, 3, and 6\u2009months of initiation of GLP\u20101RA were assessed in propensity score\u2010matched cohorts by age, sex, race, and ethnicity. Outcomes were reported as risk differences (RD) and odds ratios (OR) with 95% confidence intervals (CI).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      GLP\u20101RA therapy increased the 6\u2010month risk of any laryngeal manifestations (OR 1.19, 95% CI 1.16\u20131.21;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Higher odds were observed for cough (OR 1.46,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), foreign body sensation (OR 1.1.41,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and voice and resonance disorders (OR 1.19,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). Across agents, exenatide, liraglutide, semaglutide, dulaglutide, and lixisenatide showed significant elevated 6\u2010month risk of laryngeal manifestations (OR 1.16\u20131.91\u20131.48;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), while albiglutide and tirzepatide did not.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP\u20101RA\/GIP use in adults is linked to higher rates of laryngeal symptoms, most notably cough and voice and resonance disorders. While absolute risk differences were small, the large number of affected individuals underscores the potential clinical and public health relevance of these findings, in the context of the rapidly growing prevalence of GLP\u20101RA\/GIP use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence<\/jats:title>\n                    <jats:p>3<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/lary.70808","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:30:55Z","timestamp":1786537855000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of Glucagon\u2010Like Peptide\u20141 Receptor Analogues and Laryngeal Symptoms in Obese Adults"],"prefix":"10.1002","author":[{"given":"Priyanka","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery Medical University of South Carolina  Charleston South Carolina USA"},{"name":"Edward via College of Osteopathic Medicine  Blacksburg Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kayekjian","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery Medical University of South Carolina  Charleston South Carolina USA"},{"name":"College of Medicine University of Central Florida  Orlando Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0664-4571","authenticated-orcid":false,"given":"Shaun A.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery Medical University of South Carolina  Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Meenan","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery Medical University of South Carolina  Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1293-501X","authenticated-orcid":false,"given":"Ashli K.","family":"O\u2019Rourke","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery Medical University of South Carolina  Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"e_1_2_11_2_1","volume-title":"Drug Approval Package: Byetta (Exenatide) Injection","author":"US Food and Drug Administration","year":"2005"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14061978"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13177"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2023.10.002"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57232"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS\u201024\u201002870"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.06.003"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/924168"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.32061"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.16620"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15038"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13929"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102023\u2010329651"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2017.07.004"},{"key":"e_1_2_11_17_1","volume-title":"Real\u2010World Data for the Life Sciences and Healthcare","year":"2026"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/XCE.0000000000000321"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.27591"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3701"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126413"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S277676"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.08.1458"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm16057"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"}],"container-title":["The Laryngoscope"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lary.70808","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/lary.70808","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lary.70808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:30:56Z","timestamp":1786537856000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/lary.70808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":25,"alternative-id":["10.1002\/lary.70808"],"URL":"https:\/\/doi.org\/10.1002\/lary.70808","archive":["Portico"],"relation":{},"ISSN":["0023-852X","1531-4995"],"issn-type":[{"value":"0023-852X","type":"print"},{"value":"1531-4995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"2026-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"lary.70808"}}